24/04/2017. Our submission focused on how community pharmacy provides a vital role in the care of asthma among children and adolescents. While we were pleased to see that pharmacy was referenced twice in this consultation, we made several recommendation on how community pharmacy could be further incorporated into these Guidelines.
28/02/2017. We are supportive of integrated person centric care with a focus on improved health outcomes. Our main concern is the IT infrastructure and funding to enable the framework to be realised. Contractual arrangements need to incentivise collaboration while ensuring that community pharmacies remain separate entities from general practice.
13/02/2017. Our submission covered English communication skills, cultural awareness, rural workforce, and having a greater focus on business skills, patient-centric service provision and experiential learning in the curriculum.
26/01/2017. We supported the proposed changes to the postgraduate certificate in clinical pharmacy degree. We believe these proposed changes will help meet the current and future needs of the profession.
The Guild pledges its support for updating the strategy. We highlight the important contribution community pharmacy makes in helping older people to take charge of their own health care management, and argue for more resources to expand and enhance this important role.
The Guild received an overwhelming number of feedback responses from our members. The key message we received is clear; without any additional funding from DHBs, no solution will address the margin issue.
We are very pleased that the Ministry of Health has recognised the value that pharmacists can provide to the health sector as a whole.
In our submission, we set out our support for an expanded role for pharmacists as members of the multidisciplinary healthcare team, enhancing pharmacy services in the community, and community pharmacy’s role in the systemised delivery of health promotion and personal health messages.
We were pleased to see that pharmacists were acknowledged throughout the document and this emphasised their importance in the primary healthcare team and their ability to contribute to the healthy outcomes for patients with respiratory conditions. This document presents many opportunities for community pharmacy to contribute to achieving the best possible health outcomes for people with respiratory conditions. We welcomed the opportunity to work collaboratively with other national pharmacy organisations to develop specific services for respiratory conditions that can be provided through community pharmacy.
We stated that we were unable to support this code while there remains no explicit process to ensure recognition of the huge input required at community pharmacy level to ensure patient safety during a consumer-level recall. We looked forward to supporting the Recall code when a clear process for consumer-level recalls, including the reimbursement of direct costs incurred by community pharmacy, is included.
Overall, pharmacists expressed support for the Stage Four funding model. It should be noted that some issues raised previously continue to remain unaddressed.